Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis
- Published on 03/11/2025
- Reading time: 4 min.
Wu Jie 1, Wang Zhiqiang 2, Fu Yi 3
1 https://ror.org/0220qvk04 Key Laboratory of Hydrodynamics (Ministry of Education), School of Ocean and Civil Engineering Shanghai Jiao Tong University No.800 Dongchuan Road, Minhang District 200240 Shanghai China
2 https://ror.org/0220qvk04 Department of General Surgery Tongren Hospital, Shanghai Jiao Tong University School of Medicine 200336 Shanghai China
3 https://ror.org/03ns6aq57 Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines & School of Medical Instruments Shanghai University of Medicine & Health Sciences 201318 Shanghai China
Abstract
Background This study aimed to evaluate the efficacy and safety of docetaxel plus capecitabine (TX) and docetaxel plus epirubicin (TE) in the treatment of human epidermal growth factor 2 (HER2)-negative breast cancer.
Methods Relevant studies assessing the efficacy and safety of TX versus TE were systematically searched from PubMed, Cochrane Library, Embase, and Web of Science databases until February 6, 2025. Progression-free survival (PFS), and clinical...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
